No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BGNE240517C180000
- 0.05
- 0.000.00%
15min DelayTrading May 17 13:13 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume0 Open Interest180.00Strike Price0.00Turnover271.24%IV14.48%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type0.0336Delta0.0197Gamma3145.40Leverage Ratio-5.5509Theta0.0000Rho105.82Eff Leverage0.0010Vega
Intraday
- 5D
- 1D
News
An Intrinsic Calculation For BeiGene, Ltd. (NASDAQ:BGNE) Suggests It's 47% Undervalued
Key Insights The projected fair value for BeiGene is US$317 based on 2 Stage Free Cash Flow to Equity Current share price of US$167 suggests BeiGene is potentially 47% undervalued Analyst price t
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India
Glenmark Specialty, a subsidiary of Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296), will market Beigene's (SHA: 688235, HKG:6160) oncology medicines, Tislelizumab and Zanubrutinib, in India, acco
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
BeiGene, Ltd. BGNE is a next-gen oncology company focusing on discovering and developing innovative and affordable treatments for cancer patients worldwide.
Clinical research tool book “Everything is Visible” officially published and sold
BEIJING, May 20, 2024/PRNewswire/ -- BeiGene (NASDAQ: BGNE; Hong Kong Stock Exchange: 06160; Shanghai Stock Exchange: 688235), a global oncology treatment innovation company, today announced that “Everything Visible: Ten Scenarios for Visualization Applications in Clinical Research and Development” (hereinafter referred to as “Everything Visible”), which it co-organized with the Drug Information Association (DIA) China Digital Health Community (DHC)), has officially launched. “Everything is Visible” book cover “Everything Visible” is a systematic introduction to how data visualization can be applied to clinical medical research
Top Gap Ups and Downs on Thursday: WMT, TM, MUFG and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
BeiGene (06160) grants share options to subscribe for a total of 12,000 American Depositary Shares under the 2016 Options and Incentive Plan
BeiGene (06160) issued an announcement. On May 10, 2024, the Remuneration Committee of the Board of Directors was based on 201...
Comments
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
6
Last week’s PDUFAs:
$BeiGene(BGNE.US$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb(BMY.US$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals(VNDA.US$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
$BeiGene(BGNE.US$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb(BMY.US$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals(VNDA.US$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
20
2
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Eyenovia(EYEN.US$ $Vanda Pharmaceuticals(VNDA.US$ $Mirum Pharmaceuticals(MIRM.US$ $Madrigal Pharmaceuticals(MDGL.US$ $Geron(GERN.US$ $Bristol-Myers Squibb(BMY.US$ $2seventy bio(TSVT.US$ $Legend Biotech(LEGN.US$ $OptiNose(OPTN.US$ $Orchard Therapeutics(ORTX.US$ $Merck & Co(MRK.US$ $Akebia Therapeutics(AKBA.US$ $AstraZeneca(AZN.US$ $Liquidia(LQDA.US$ $Esperion Therapeutics(ESPR.US$ $Regeneron Pharmaceuticals(REGN.US$ $BeiGene(BGNE.US$
$Eyenovia(EYEN.US$ $Vanda Pharmaceuticals(VNDA.US$ $Mirum Pharmaceuticals(MIRM.US$ $Madrigal Pharmaceuticals(MDGL.US$ $Geron(GERN.US$ $Bristol-Myers Squibb(BMY.US$ $2seventy bio(TSVT.US$ $Legend Biotech(LEGN.US$ $OptiNose(OPTN.US$ $Orchard Therapeutics(ORTX.US$ $Merck & Co(MRK.US$ $Akebia Therapeutics(AKBA.US$ $AstraZeneca(AZN.US$ $Liquidia(LQDA.US$ $Esperion Therapeutics(ESPR.US$ $Regeneron Pharmaceuticals(REGN.US$ $BeiGene(BGNE.US$
21
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
6
The research is done by the respective broker and I do not endorse any of them. Just sharing here for information and reading pleasure.
alphaedgeinvest...
$BEIGENE(06160.HK$ $BeiGene(BGNE.US$
alphaedgeinvest...
$BEIGENE(06160.HK$ $BeiGene(BGNE.US$
Read more